Elicio Therapeutics (ELTX) Invested Capital (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Invested Capital data on file, last reported at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 116.14% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 million (down 116.14% YoY), and the FY2025 full-year result was $11.6 million, up 202.86% from the prior year.
• Invested Capital for Q1 2026 stood at -$1.4 million, down from $11.6 million in the prior quarter.
• Across five years, Invested Capital topped out at $23.6 million in Q2 2023 and bottomed at -$109.9 million in Q1 2023.
• The 5-year median for Invested Capital is -$1.4 million (2026), against an average of -$24.8 million.
• The widest annual swing landed in 2022, when Invested Capital plunged 248.34%; it then soared 816.34% in 2025.
• A 5-year view of Invested Capital shows it stood at -$102.1 million in 2022, then surged by 111.13% to $11.4 million in 2023, then tumbled by 199.46% to -$11.3 million in 2024, then surged by 202.86% to $11.6 million in 2025, then plunged by 112.35% to -$1.4 million in 2026.
• The last three Invested Capital figures came in at -$1.4 million (Q1 2026), $11.6 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.

Peer Comparison